Dr Appleby will ensure that the scientific direction of the CGT Catapult remains at the forefront of translational research, bringing to the group “decades of industry experience in cell and gene therapies and drug development”.
He is currently chief scientific officer for Cell and Gene Therapy at the GSK Rare Diseases Unit.
